Andrew Wotherspoon

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

Ian Chau, David Cunningham, David González de Castro et al. · The Lancet Oncology · 2013 · 728 citations

Medicine, Oncology, Pharmacology +13

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

Frederick Arce Vargas, Andrew J.S. Furness, Kevin Litchfield et al. · Cancer Cell · 2018 · 585 citations · Full text

Medicine, Immunology, Oncology +17

Mismatch Repair Deficiency, Microsatellite Instability, and Survival

Elizabeth Smyth, Andrew Wotherspoon, Clare Peckitt et al. · JAMA Oncology · 2017 · 521 citations · Full text

Life Sciences, Molecular Genetics, Oncology +17

Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imaging–Defined Poor-Risk Rectal Cancer

Ian Chau, Gina Brown, David Cunningham et al. · Journal of Clinical Oncology · 2006 · 481 citations · Full text

Medicine, Oncology, Surgery +17

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases

Sophia Frentzas, Ève Simoneau, Victoria L. Bridgeman et al. · Nature Medicine · 2016 · 436 citations

Medicine, Cancer Biology, Oncology +16